ESPR - Esperion Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.3500
-0.0100 (-0.74%)
At close: 04:00PM EDT
1.3500 0.00 (0.00%)
After hours: 07:01PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.3600
Open1.3600
Bid1.3400 x 21500
Ask1.4100 x 1800
Day's Range1.3200 - 1.3800
52 Week Range1.1200 - 8.8700
Volume1,841,284
Avg. Volume3,737,228
Market Cap127.862M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-3.2800
Earnings DateJul 31, 2023 - Aug 04, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.19
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ESPR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks

    Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023

    ANN ARBOR, Mich., June 08, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of key late breaking sessions at the American Diabetes Association’s 83rd Scientific Sessions taking place on June 23-26, 2023, in San Diego, CA. Session Type: Late Breaking Poster Session (printed poster) Date/Time: June 24, 2023, 11:30 AM – 12:30 PM PT Abstract Title: LDL Cholesterol Reduction and Cardiovascular Outcomes in High-Risk Primary Prevention Patients Location: Poster Halls B-

  • Simply Wall St.

    When Will Esperion Therapeutics, Inc. (NASDAQ:ESPR) Turn A Profit?

    Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...

  • GlobeNewswire

    Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023

    ANN ARBOR, Mich., June 05, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at ENDO 2023 taking place June 15-18, 2023, in Chicago, IL. On DemandSession Type:Rapid Fire Presentation #10775 Date/Time:June 15, 2023, 12:30 -1:30 p.m. CT Abstract Title:Comparison Of The Cardiovascular Benefits Of Bempedoic Acid With Statins- Analysis By The Cholesterol Treatment Trialists’ Methodology Presenter:A. Michael Lincoff, MD, Vice Chairman for Research, Dep

  • GlobeNewswire

    Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

    – Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering – – Anticipated approvals in U.S. in the first half of 2024 – ANN ARBOR, Mich., June 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has submitted Supplemental New Drug Applications (sNDA) to the U.S. Food and Drug Administration (FDA) for the Company’s oral non-statin products NEXLETOL and NEXLIZET. In its sNDAs, Esperion seeks to add the use of both NEXLETOL

  • GlobeNewswire

    Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

    ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 13, 2023 (the “Proxy Statement”). The Annual Meeting, originally scheduled to be held on May 25, 2023 at 8:00 a.m. Eastern Time, and subsequen

  • GlobeNewswire

    Esperion to Participate in Jefferies Healthcare Conference

    ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th, 2023 at 9:00 AM ET. The Esperion management team will also be available to host 1 on 1 investor meetings. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion webs

  • GlobeNewswire

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement materi

  • Zacks

    Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

    Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

  • Zacks

    Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Esperion Reports First Quarter 2023 Financial Results

    – U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global Regulatory Filings Anticipated in 1H 2023 – – Entered into Commercial Partnership with Currax Pharmaceuticals – ANN ARBOR, Mich., May 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2023 a

  • GlobeNewswire

    Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

    – Gibson Dunn Files Amended Complaint with Powerful New Evidence –ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300 million milestone payment to Esperion

  • GlobeNewswire

    Esperion to Participate in JMP Securities Life Sciences Conference

    ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approxim

  • GlobeNewswire

    Esperion to Participate in Bank of America Securities 2023 Health Care Conference

    ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America Securities 2023 Health Care Conference on Thursday, May 11th, 2023, at 11:40 AM PDT. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be availa

  • Zacks

    Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Esperion to Report First Quarter 2023 Financial Results May 9, 2023

    ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Following the release, company management will host a webcast at 8:00 a.m. ET to discuss financial results and business progress. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN. Already registered? Access with your PIN

  • GlobeNewswire

    Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

    – Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of Currax’s 72 sales representatives to co-promote NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

  • InvestorPlace

    7 Very Undervalued Penny Stocks to Buy in April 2023

    Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price. It is also worth noting that penny stocks are highly risky and it goes without saying that losses aren’t uncommon. In other words, don’t treat these stocks the same as their more stable counterparts, and only invest what you can afford to lose. That said, the penny stocks listed here are interesting and fall, for the most

  • GlobeNewswire

    Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

    ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham’s 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available ap

  • Zacks

    Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) wa

  • GlobeNewswire

    Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock in a registered direct offering priced at-the-market under

  • Simply Wall St.

    Analysts Just Slashed Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) EPS Numbers

    The latest analyst coverage could presage a bad day for Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), with the analysts...

  • Zacks

    Esperion (ESPR) Plummets 54% Over Milestone Payment Row

    An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

  • Investing.com

    5 big analyst cuts: First Republic stock slashed on 'unprecedented uncertainty' | Pro Recap

    Atlantic Equities downgraded First Republic Bank (NYSE:FRC) to Neutral from Overweight - and it is withdrawing its price target on the stock, as "the exceptionally high level of uncertainty makes providing forecasts challenging." Wedbush likewise downgraded the shares, although JPMorgan reiterated the stock as a Top Pick and its Overweight rating on First Republic, saying it sees "considerable" EPS upside after the largest U.S. banks - Bank of America (NYSE:BAC), Citigroup (NYSE:C), JPMorgan (NYSE:JPM), and Wells Fargo (NYSE:WFC), among others - committed $30 billion in uninsured deposits to boost First Republic's liquidity. Esperion Therapeutics (NASDAQ:ESPR) was downgraded at Northland Capital Markets and BofA Securities after the company reported that Daiichi Sankyo Europe (DSE), its European partner, disagrees with its assessment that CLEAR Outcomes data would support milestone payments.